To the Editor The authors of the MDCO-216 Infusions Leading to Changes in Atherosclerosis: a Novel Therapy in Development to Improve Cardiovascular Outcomes—Proof of Concept IVUS, Lipids, and Other Surrogate Biomarkers (MILANO-PILOT) trial1 conclude that there is an uncertainty regarding the therapeutic potential of targeting high-density lipoprotein (HDL). Although we concur that recent studies have not demonstrated positive outcomes with HDL-targeted therapies, this skepticism should not be based on data from this MILANO-PILOT trial.1
Garcia-Ropero A, Santos-Gallego CG, Badimon JJ. High-Density Lipoprotein–Targeted Therapies—Not Dead Yet. JAMA Cardiol. 2018;3(12):1254–1255. doi:10.1001/jamacardio.2018.3962
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.